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Influenza has long been a global public health priority be-
cause of the threat of another global pandemic. Although 
data are available for the annual burden of seasonal influ-
enza in many developed countries, fewer disease burden 
data are available for low-income and tropical countries. In 
recent years, however, the surveillance systems created 
as part of national pandemic preparedness efforts have 
produced substantial data on the epidemiology and impact 
of influenza in countries where data were sparse. These 
data are leading to greater interest in seasonal influenza, 
including implementation of vaccination programs. How-
ever, a lack of quality data on severe influenza, nonrespi-
ratory outcomes, and high-risk groups, as well as a need 
for better mathematical models and economic evaluations, 
are some of the major gaps that remain. These gaps are 
the focus of multilateral research and surveillance efforts 
that will strengthen global efforts in influenza control in 
the future.
Influenza has long been a global public health priority because of the ever-present threat of another global 
pandemic. In addition, many countries (especially in more 
affluent, temperate areas) prioritize influenza prevention 
and control programs because of the annual effects of sea-
sonal influenza. The 3 influenza pandemics that occurred 
during the 20th century clearly illustrated the major im-
pact from the global spread of a new influenza A virus (1) 
and spurred early vaccine development (2,3). The reemer-
gence of avian influenza A(H5N1) in Asia in 2004 served 
as a reminder of this threat and brought about an accelera-
tion of national and international efforts to prepare for the 
next pandemic (4). These efforts, including the expansion 
of influenza surveillance and laboratory capacity, contrib-
uted to a more effective response during the 2009 influ-
enza A(H1N1) pandemic (5).
Although the threat of novel influenza A viruses and 
pandemics has mobilized national preparedness efforts, in 
many parts of the world the importance of seasonal epi-
demics of influenza has been relatively underappreciated. 
On the basis of findings from recent influenza respiratory 
mortality studies, including estimates from a study con-
ducted by Iuliano et al (6), the World Health Organization 
(WHO) has indicated that 290,000–650,000 respiratory 
deaths from seasonal influenza epidemics occur annually 
(7). Most high-income countries, where substantial work 
to document the disease burden from annual influenza epi-
demics has been conducted, have longstanding and robust 
influenza vaccination programs (8); in these settings, the use 
of influenza antiviral drugs and antibiotics to treat influen-
za-associated lower respiratory tract infections is relatively 
routine. These strategies have likely resulted in a reduction 
in the burden of disease as well as improved clinical out-
comes for patients with influenza. In tropical and low- and 
middle-income countries (LMICs), seasonal influenza has 
often been viewed as a disease of relevance primarily to 
industrialized countries. The historical paucity of data on 
influenza from these settings has likely contributed to this 
view. More data on influenza burden in these locations are 
needed to make compelling arguments to policy makers 
for investments in seasonal influenza control and preven-
tion. These data are particularly important in the light of 
challenges related to the variable effectiveness of current 
vaccines (9) and the programmatic and economic difficul-
ties in conducting annual influenza vaccination programs 
or in implementing appropriate use of antivirals for treat-
ment in LMICs. The resulting relative underuse of vaccines 
in many LMICs represents important missed opportunities 
for disease prevention (10). Furthermore, the lack of an-
tiviral drug treatment and influenza vaccination programs 
for reduction of seasonal influenza burden in these settings 
also jeopardizes the capacity for effective responses when 
the next pandemic emerges because national pandemic re-
sponse plans rely, in part, on the timely and efficient use of 
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medical countermeasures, such as antiviral drugs and vac-
cines for pandemic viruses (11,12).
Progress, but Gaps Remain
The growth of influenza surveillance and research in the 
past 10 years has generated substantial new data on the epi-
demiology and risk from influenza around the world, no-
tably in tropical countries and LMICs (13–16). These data 
have confirmed that influenza is a major cause of hospital-
ization and severe acute respiratory disease in all settings, 
whether rich or poor, tropical or temperate, urban or rural 
(17–19), and that the risk for severe influenza outcomes 
might be higher in LMICs than in high-income countries 
(20). In South Africa, for instance, rates of influenza-asso-
ciated mortality among the elderly were 3–4 times higher 
than those among the elderly in the United States (21). One 
global estimate of childhood influenza deaths indicated that 
99% of all influenza-associated deaths among children <5 
years of age were in LMICs (18). That this finding is true 
for influenza, as it is for other infectious diseases, is not 
surprising, and similarly, is likely the result of differential 
access to medical care and preventive strategies, coupled 
with the prevalence of certain high-risk conditions and the 
underlying age structure of the populations. In some LMICs 
that have collected robust disease burden information in the 
past decade, vaccine programs have expanded (22–24). In 
addition, disease burden data from these settings were one 
driving factor for updating of the WHO influenza vaccine 
recommendations issued in 2012 by the WHO Strategic 
Advisory Group of Experts (25).
However, although data on influenza disease burden 
have expanded in recent years, considerable gaps persist. 
First, high-quality and up-to-date estimates of the extent 
of severe influenza at global and regional levels are needed 
to inform global policymakers and public health advocates 
as they set their priorities. Although new estimates of the 
global respiratory mortality rates attributable to influenza 
are available (6), additional models that take advantage 
of the expansion in influenza surveillance and laboratory 
confirmation, especially in tropical countries and LMICs, 
should yield more accurate country- and region-specific 
disease estimates. Second, at the country level, too many 
LMICs have yet to develop reliable national estimates 
of the full extent of influenza disease that would enable 
evidence-based decisions about local influenza preven-
tion investments. Third, the ability to target vaccination 
campaigns to key populations within a country depends 
on having reliable data on the burden of disease and on 
the possible effect of vaccination among specific high-risk 
target groups. The value of risk group–specific estimates 
was evident during the 2009 pandemic, when data on the 
high risk for severe outcomes among pregnant women led 
to aggressive efforts to vaccinate and appropriately treat 
this group and convince obstetricians to recommend and 
offer vaccines (26,27); this effort provided data for the 
WHO Strategic Advisory Group of Experts’ 2012 rec-
ommendations (25). Conversely, the scarcity of adequate 
data on severe disease among pregnant women during 
seasonal epidemics was one reason cited by the Global 
Alliance for Vaccines and Immunizations for their deci-
sion against opening an investment window to fund low-
income countries to vaccinate pregnant women as part of 
their most recent vaccine investment strategy (28). Data 
have long indicated that persons with specific underlying 
diseases are at high risk for severe influenza, but without a 
better understanding of the burden of the disease in these 
groups in countries considering vaccination policies, ex-
pecting policymakers to invest in programs to target them 
is unrealistic. Few data have been collected outside of 
high-income countries on other components of the health 
burden, especially the contribution of influenza infections 
to illness and death from underlying diseases made worse 
by influenza, such as cardiac or chronic pulmonary dis-
eases (29), and on non–health-related effects of influenza, 
such as the economic burden and effect on productivity 
(30). Data on each of these components will advance de-
cisions on the rational use of resources to prevent influ-
enza, and the need for these data was highlighted in the 
recent revision of the WHO Influenza Research Agenda 
(31).
Ongoing Work to Address the Gaps  
and Future Needs
Substantial work is under way to fill these gaps. WHO has 
created a robust program to collect data on global and na-
tional influenza burden and to better determine the burden 
among risk groups. Two manuals have been developed 
to guide member states’ efforts to measure influenza dis-
ease (32) and economic burden (33) from data collected 
through ongoing influenza surveillance. Both manuals are 
being used by countries, in part, because of the Pandemic 
Influenza Preparedness Implementation Plan that has fa-
cilitated country-level disease burden estimation in many 
countries around the world (34). These efforts have led 
to recent publications from LMICs, supported by WHO, 
that provide important influenza disease burden data (34). 
WHO has also sponsored reviews of influenza-associated 
disease burden among pregnant women and their infants 
(35,36). Additional multinational collaborations are under 
way that will continue to develop more credible global in-
fluenza mortality and hospitalization estimates based on 
recent work to develop national estimates, as well as in-
formation on influenza burden among key high-risk groups 
(Figure) (6). These efforts take advantage of the recent in-
crease in local- or country-level studies that have extended 
data beyond temperate, high-income settings. WHO is also 
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mapping existing knowledge from published literature to 
enable easier access to available data and identify key re-
maining gaps. Finally, WHO is developing a collection of 
economic tools to support the use of disease burden data to 
estimate the overall costs, the cost of vaccination programs, 
and the cost-effectiveness of vaccination.
In addition, other global partners are working in this 
area. The US Centers for Disease Control and Prevention 
has established collaborations with >50 countries around 
the world to strengthen surveillance and laboratory testing 
capacities, including expanding global capacity for genetic 
sequencing, that have produced data on influenza epide-
miology and disease burden. The Multinational Influenza 
Seasonal Mortality Study (37), coordinated by the Fogarty 
Center at the US National Institutes of Health, has been 
working with countries to estimate influenza mortality from 
diverse settings since 2001. Institute Pasteur and Agence de 
Médecine Préventive have worked in low-income countries 
in Africa to build surveillance capacity. More recently, the 
Global Health Security Agenda has increased resources to 
many developing countries to strengthen surveillance and 
response capabilities that will also lead to new data on the 
relative burden of influenza compared with other infectious 
diseases. The European Center for Disease Control has de-
veloped free software that supports countries in the region 
to estimate the burden of influenza and other infectious dis-
eases (38). These efforts have led to a substantial increase 
in country-specific estimates of burden in the past 5 years 
and promise to lead to many more in the next 1–2 years.
Much has been accomplished, and in the next few 
years a more complete picture of the burden of influenza 
will be available. However, more work will still be needed 
if we are to measure the full burden of influenza and, more 
important, the preventable burden. This knowledge will en-
able decision-makers to weigh the value of vaccination and 
encourage the use of antiviral drugs against myriad other 
health needs in their countries, as well as providing addi-
tional impetus for the development of newer, more effec-
tive treatments and vaccines. Vaccine probe studies have 
been proposed as a method to measure the preventable frac-
tion of disease burden, focusing the studies on outcomes 
of greatest public health interest (e.g., pneumonia and 
death rates). Whether vaccine probe studies could be de-
signed sufficiently to account for the variable and relatively 
modest vaccine efficacy and variability in annual disease 
burden that is characteristic of influenza is uncertain but 
should be further discussed (39). Finally, the year-to-year 
variability in disease burden requires that data be collected 
over multiple years and that new methodologic approaches 
be developed and validated to measure burden in settings 
with year-round circulation of influenza (40)
Conclusions
Influenza has long been a compelling example of a global 
pandemic threat, but the annual disease burden has been 
relatively underappreciated, leading to missed opportu-
nities for disease reduction and prevention. Convincing 
evidence of seasonal burden of disease in more settings 
and for a wider array of influenza outcomes will be the 
foundation of arguments for strengthening programs to 
control annual influenza and to reduce the threat of future 
pandemics (41,42).
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Figure. Countries with burden of disease estimates that have agreed to share data for the global estimate of influenza mortality and 
influenza-associated hospitalizations, as of April 2017: blue, morbidity estimates; brown, mortality estimates; green, morbidity and 
mortality estimates; white, data not available.
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Influenza (flu) is a contagious respiratory illness 
caused by influenza viruses. It can cause mild 
to severe illness. Serious outcomes of flu infec-
tion can result in hospitalization or death. Some 
people, such as older people, young children, 
and people with certain health conditions, are 
at high risk for serious flu complications. The 
best way to prevent the flu is by getting vac-
cinated each year.
Influenza
®
